Danaher Corporation (DHR)vsCheck-Cap Ltd. (MBAI)
DHR
Danaher Corporation
$184.30
-0.38%
HEALTHCARE · Cap: $117.48B
MBAI
Check-Cap Ltd.
$1.53
-8.38%
HEALTHCARE · Cap: $10.67M
Smart Verdict
WallStSmart Research — data-driven comparison
DHR leads profitability with a 14.9% profit margin vs 0.0%. MBAI trades at a lower P/E of 2.1x. DHR earns a higher WallStSmart Score of 58/100 (C).
DHR
Buy58
out of 100
Grade: C
MBAI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Intrinsic value data unavailable for MBAI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 120 in profit
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MBAI
The strongest argument for MBAI centers on P/E Ratio, Return on Equity, Debt/Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : MBAI
The primary concerns for MBAI are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
DHR carries more volatility with a beta of 0.84 — expect wider price swings.
DHR is growing revenue faster at 3.7% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (58/100 vs 28/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Check-Cap Ltd.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company is headquartered in Isfiya, Israel.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?